A prospective study of 5-Fu in the treatment of prostatic hyperplasia was commenced in 1981. The short term results were fair in 70% of 43 patients. Atrophy of the glandular tissue could be observed on histopathologic examinaion. The study showed that the larger the glandular component the better was the therapeutic effect. If abundant fibromuscular tissue was present in the gland the treatment was unsatisfactory. Abnormal anatomy of the bladder neck, represented a contraindication to medical treatment.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Altwein JE (1974) A relationship of benign prostatic hypertrophy with hormon. Urologe 13:41
Basinger GT et al (1974) Antiandrogenic effect of spironolactone in rats. J Urol 111:77
Chen L et al (1976) Mechanism of action of the sex steroid hormons. New Engl J Med 294:1322
Dorfman RI (1963) The antiandrogenic activity of 5-Fluorouracil. Steroids 2:555
Horton R, et al (1975) Altered blood androgens in elderly men with prostatic hyperplasia. J Clin Endocrinol Metab 41:793
Smith RB et al (1973) Cyproterone acetate in the treatment of advanced carcinoma of prostate. J Urol 110:106
About this article
Cite this article
Wei, X.Y., Zhou, X.M. 5-fluorouracil (5-Fu) in the treatment of prostatic hyperplasia. Urol. Res. 15, 35–37 (1987). https://doi.org/10.1007/BF00256333
- Prostatic hyperplasia
- Medical treatment